M-M-RVaxPro
measles, mumps and rubella vaccine (live)
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for M-M-RVaxPro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use M-M-RVaxPro.
For practical information about using M-M-RVaxPro, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
M-M-RVaxPro : EPAR - Summary for the public (PDF/74.57 KB)
First published: 09/08/2006
Last updated: 29/05/2017 -
-
List item
M-M-RVaxPro : EPAR - Risk-management-plan summary (PDF/1.76 MB)
First published: 10/12/2019
Authorisation details
Product details | |
---|---|
Name |
M-M-RVaxPro
|
Agency product number |
EMEA/H/C/000604
|
Active substance |
|
International non-proprietary name (INN) or common name |
measles, mumps and rubella vaccine (live)
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
J07BD52
|
Publication details | |
---|---|
Marketing-authorisation holder |
MSD VACCINS
|
Revision |
26
|
Date of issue of marketing authorisation valid throughout the European Union |
05/05/2006
|
Contact address |
162 avenue Jean Jaurès
69007 Lyon France |
Product information
26/10/2020 M-M-RVaxPro - EMEA/H/C/000604 - IA/0104/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Vaccines
Therapeutic indication
M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older.
For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.